Circulating Soluble ACE2 Plays an Independent Role to Protect against Vascular Damage in Diabetic Mice.

Angiotensin-converting enzyme 2 (ACE2) DNA minicircle angiotensin II atherosclerosis diabetes

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
18 May 2022
Historique:
received: 31 03 2022
revised: 11 05 2022
accepted: 13 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Circulating levels of soluble ACE2 are increased by diabetes. Although this increase is associated with the presence and severity of cardiovascular disease, the specific role of soluble ACE2 in atherogenesis is unclear. Previous studies suggested that, like circulating ACE, soluble ACE2 plays a limited role in vascular homeostasis. To challenge this hypothesis, we aimed to selectively increase circulating ACE2 and measure its effects on angiotensin II dependent atherogenesis. Firstly, in

Identifiants

pubmed: 35624851
pii: antiox11050987
doi: 10.3390/antiox11050987
pmc: PMC9138042
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Health and Medical Research Council
ID : 2016/GNT1127526

Références

Circulation. 1993 May;87(5 Suppl):IV7-13
pubmed: 8485836
Kidney Int. 2017 Jun;91(6):1336-1346
pubmed: 27927599
Circ Res. 2010 Oct 1;107(7):888-97
pubmed: 20671240
Lancet. 2020 Oct 3;396(10256):968-976
pubmed: 33010842
J Clin Invest. 2005 Dec;115(12):3494-505
pubmed: 16294222
Circulation. 2002 Jul 9;106(2):246-53
pubmed: 12105166
Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2281-90
pubmed: 16055515
PLoS One. 2014 Jan 15;9(1):e85958
pubmed: 24454948
J Mol Med (Berl). 2015 Sep;93(9):1003-13
pubmed: 25874965
J Hypertens. 2012 Feb;30(2):375-83
pubmed: 22179088
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2195-2203
pubmed: 28935757
Circulation. 2002 Mar 5;105(9):1135-43
pubmed: 11877368
Circulation. 2007 Apr 24;115(16):2178-87
pubmed: 17420349
J Clin Invest. 2000 Jun;105(11):1605-12
pubmed: 10841519
J Biol Chem. 2005 Aug 26;280(34):30113-9
pubmed: 15983030
Am J Cardiol. 2006 Jul 1;98(1):121-8
pubmed: 16784934
Diabetes. 2005 Sep;54(9):2628-37
pubmed: 16123351
Nature. 2002 Jun 20;417(6891):822-8
pubmed: 12075344
Clin Sci (Lond). 2012 Nov;123(9):547-55
pubmed: 22616837
Exp Physiol. 2013 Jan;98(1):109-22
pubmed: 22750422
Am J Physiol Lung Cell Mol Physiol. 2012 Mar 1;302(5):L474-84
pubmed: 22180660
Circulation. 2004 Mar 30;109(12):1536-42
pubmed: 15023892
Curr Drug Targets. 2017;18(11):1301-1313
pubmed: 27469342
Hypertension. 2006 Apr;47(4):718-26
pubmed: 16505206
Thromb Res. 2009 May;124(1):110-5
pubmed: 19195683
Am J Cardiol. 2021 May 1;146:15-21
pubmed: 33539861

Auteurs

Chris Tikellis (C)

Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.

Gardner N Robinson (GN)

Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.

Carlos J Rosado (CJ)

Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.

Duygu Batu (D)

Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.

Maria A Zuniga-Gutierrez (MA)

Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.

Raelene J Pickering (RJ)

Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.

Merlin C Thomas (MC)

Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.

Classifications MeSH